Home › Myelodysplastic Syndromes › Kansas

Pag-aaral pangklinika para sa Myelodysplastic Syndromes sa Kansas

5 pag-aaral para sa Myelodysplastic Syndromes ang naghahanap ng mga kalahok sa mga site sa Kansas.

Mga Lungsod sa Kansas

Opisyal na teksto ng pag-aaral (English)

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

University of Kansas Clinical Research Center, Fairway
University of Kansas Cancer Center, Kansas City
University of Kansas Hospital-Westwood Cancer Center, Westwood

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT06577441

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

University of Kansas Clinical Research Center, Fairway
HaysMed, Hays
University of Kansas Cancer Center, Kansas City
at 7 pa

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT05564390

A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

University of Kansas Medical Center Research Institute, Inc., Kansas City

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Abr 13, 2026 · NCT06146257

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

University of Kansas Cancer Center, Westwood

Nagre-recruitPhase 1

Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Mar 25, 2026 · NCT03533816

Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02

University of Kansas Cancer Center, Fairway

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Hun 9, 2020 · NCT04167696

Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.